© 2018 Ciorba Lab

Clinical Studies - Principle Investigator or Key Personnel

  • ​A randomized controlled trial of a lactobacillus probiotic to prevent GI side effects in patients undergoing chemoradiation for gastrointestinal malignancy. Role: PI. Investigator initiated.  Funding from Longer Life Foundation and Siteman Cancer Center/NCI     


  • A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn’s Disease (C13007) Sponsor: Takeda Millennium 


  • A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis (C13006) Sponsor: Takeda Millennium


  •  A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease (C13008) Sponsor: Takeda Millennium


  • A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients with Moderate to Severe Crohn’s Disease (C13011) Sponsor: Takeda Millennium 


  • A Phase 2B, Multi-Center, Randomized, Double − blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT − 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease (Abbott M10-222) Sponsor: Abbott


  • Protocol MDX1100-06, A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Subjects with Active Ulcerative Colitis  Sponsor: Medare


  • Topical 0.1% Tacrolimus Ointment in the Treatment of Perianal Crohn’s Disease Sponsor: PI on Investigator Initiated Study supported by WUSM/Tap Pharma Grant administered via GI division